BRIEF—Orexo wins appeal to confirm validity of Zubsolv patent

Sweden’s Orexo has won an appeal to overturn an adverse decision previously rendered by the District Court of Delaware.

The litigation relates to Actavis’s generic Zubsolv (buprenorphine/naloxone) products, which Orexo alleges infringe certain of its patents.

The decision at the Court of Appeals for the Federal Circuit means that the validity of the ‘330 patent until 2032 has been confirmed.

Chief executive Nikolaj Sørensen said: “We have continuously been confident in our IP protecting Zubsolv, not only in the US, but on a global basis."

"The patent litigation process with Actavis has been a lengthy and resource consuming process for Orexo and we are pleased we can now fully focus on growing our Zubsolv business and expanding our product pipeline, without the uncertainty created by the patent litigation process.”